<DOC>
	<DOCNO>NCT00346229</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal doxorubicin , work different way stop growth tumor cell , either kill cell stop dividing . Hyperthermia therapy kill tumor cell heat several degree normal body temperature . Giving temperature-sensitive liposomal doxorubicin together hyperthermia may kill tumor cell . PURPOSE : This phase I trial study side effect best dose temperature-sensitive liposomal doxorubicin give together hyperthermia treat woman locally recurrent breast cancer .</brief_summary>
	<brief_title>Temperature-Sensitive Liposomal Doxorubicin Hyperthermia Treating Women With Locally Recurrent Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose temperature-sensitive liposomal doxorubicin ( ThermoDox™ ) use combination local-regional hyperthermia woman locally recurrent breast cancer . - Determine pharmacokinetic profile ThermoDox™ use multiple-course dosing . OUTLINE : This dose-escalation study temperature-sensitive liposomal doxorubicin ( ThermoDox™ ) . Patients receive ThermoDox™ IV 30 minute immediately follow hyperthermia chest wall/axilla 1-2 hour day 1 . Treatment repeat every 21-35 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ThermoDox™ ( without standard-dose granulocyte colony-stimulating factor [ G-CSF ] support ) maximum tolerate dose ( MTD ) determine . The MTD without G-CSF support define dose precede 2 3 2 6 patient experience dose-limiting toxicity ( DLT ) . At least 6 patient treated MTD . If DLT neutropenia &gt; 1 6 patient treat dose level , additional cohort 3-6 patient receive escalate dos ThermoDox™ G-CSF support ( standard-dose G-CSF standard-dose pegfilgrastim ) MTD determine . The MTD G-CSF support define dose precede 2 3 2 6 patient experience DLT addition G-CSF support . Quality life pain assessed baseline , prior course 3 5 , 21-42 day completion therapy . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Locally recurrent disease involve chest wall and/or overlie skin Clinically biopsy proven disease chest wall area measure ≥ 1 cm Overall surface extent tumor ≤ two 16 x 16 cm field Tumor thickness ≤ 3 cm clinical exam CT scan MRI Disease extent chest wall exceed criterion allow provide local therapy available Patients axillary disease involvement must meet criterion order eligible Prior skin change consistent inflammatory breast cancer allow Distant metastasis ( exclude know brain metastasis ) allow No resectable chest wall recurrence site metastatic disease No refractory pain secondary metastatic disease Must undergone prior local radiotherapy chest wall breast adjuvant metastatic setting Must progress ≥ 1 course hormonal therapy metastatic disease ( tumor estrogen receptor positive progesterone receptor positive ) AND ≥ 1 course chemotherapy Prior contralateral breast malignancy allow provide previously treat chemotherapy Hormone receptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify Zubrod performance status 01 OR Karnofsky performance status 90100 % Not pregnant Negative pregnancy test Fertile patient must use effective contraception Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Bilirubin normal alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN leave ventricular ejection fraction ( LVEF ) ≥ 50 % multiple gated acquisition scan ( MUGA ) echocardiogram No nonhealing wound active infection area chest wall No clinically significant finding baseline evaluation , include laboratory physical examination , vital sign , ECG No prior sensitivity ( e.g. , rash , dyspnea , wheeze , urticaria , symptom ) attribute anthracyclines liposomally encapsulate drug No prior concurrent primary malignancy except melanoma situ , nonmelanoma skin cancer , squamous cell carcinoma , noninvasive cervical carcinoma No history follow : Cardiac ischemia acute coronary artery syndrome , myocardial infarction ( MI ) , cerebral vascular accident , abnormal cardiac stress test within last 6 month Coronary artery disease ( include nonQ wave MI ) Uncontrolled hypertension cardiomyopathy Cardiac valvular surgery open heart surgery Known structural heart disease No serious medical illness include , limited , follow : Congestive heart failure Lifethreatening cardiac arrhythmia Acute chronic liver disease No major psychiatric illness require inpatient treatment within past 3 month would preclude obtain informed consent No concurrent device condition might interfere hyperthermia portion trial , include follow : Functioning cardiac pacemaker Metal plat , rod , prosthesis chest wall Severe numbness and/or tingle chest wall breast Skin graft and/or flap breast chest wall Unstable cardiovascular pulmonary status No known allergy egg egg product PRIOR CONCURRENT THERAPY : See Disease Characteristics More 3 month since prior major surgery No prior therapy anthracyclines exceed follow dos : Doxorubicin hydrochloride &gt; 450 mg/m^2 Epirubicin hydrochloride &gt; 900 mg/m^2 More 42 day since prior trastuzumab ( Herceptin® ) More 90 day since prior radiotherapy involve chest wall area No concurrent systemic anticancer therapy , include hormonal therapy , chemotherapy , investigational anticancer therapy No concurrent radiotherapy , include radiotherapy pain control No concurrent administration follow drug : Amphotericin B injection Antithyroid agent Azathioprine Chloramphenicol Colchicine Flucytosine Ganciclovir Interferon Plicamycin Zidovudine Sulfinpyrazone Probenecid Cyclosporine Phenobarbital Phenytoin Streptozocin Live vaccine Concurrent bisphosphonates palliation bony metastasis allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stage III B breast cancer</keyword>
	<keyword>stage III C breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>